Science Park
2 Snunit St. POB 455
Karmiel 2161401
Israel
972 4 902 8100
https://www.protalix.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 208
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Dror Bashan | President, CEO & Director | 473,16k | N/D | 1967 |
Mr. Eyal Rubin M.B.A. | Senior VP, CFO, Treasurer & Corporate Secretary | 813,73k | N/D | 1976 |
Mr. Yaron Naos | Senior Vice President of Operations | 409,95k | N/D | 1964 |
Ms. Yael Fellous | Vice President of Human Resources | N/D | N/D | N/D |
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
L'ISS Governance QualityScore di Protalix BioTherapeutics, Inc. al 1 aprile 2024 è 5. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 8; diritti degli azionisti: 1; retribuzione: 8.